publication date: Dec. 6, 2019
NCI Trials
NCI Trials for December 2019
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
For further information, contact the principal investigator listed.
Phase I – 10291
A Phase 1b Study of M6620 in Combination with Radiation Therapy to Overcome Therapeutic Resistance in Chemotherapy Resistant Triple Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer
Mayo Clinic Cancer Center LAO
Mutter, Robert W.
(507) 284-8227
Phase I/II – PBTC-055
Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine (HCQ) for BRAF V600E-Mutant or Trametinib and HCQ for BRAF Fusion/Duplication Positive or NF1-Associated Recurrent or Progressive Gliomas in Children and Young Adults
Pediatric Brain Tumor Consortium
Hoffman, Lindsey M.
(602)9330920
Phase II – 10222
A Phase II Study of Olaparib and AZD6738 in Isocitrate Dehydrogenase (IDH) Mutant Solid Tumors
Yale University Cancer Center LAO
Hafez, Navid
(203) 785-3333
Phase II – 10284
Phase II Trial of Avelumab (BavencioÆ) with IL-15 in Subjects with Clear-Cell Renal Carcinoma
NCI Center for Cancer Research
Conlon, Kevin C.
(301) 402-2913
Phase III – EA2186
A Randomized Phase III Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment NaÔve Metastatic Pancreatic Cancer
ECOG-ACRIN Cancer Research Group
Dotan, Efrat
(215) 728-2500
To access this members-only content, please log in.Institutional subscribers, please
log in with your IP.
If you're not a subscriber why not
join today? To gain access to the members only content
click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.
